You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tqb2450

Showing 1 - 21 of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Squamous Non-Small Cell Lung Carcinoma Trial in Beijing, Tianjin, Kunming (TQB2450, Anlotinib HCl capsule, Tislelizumab

Not yet recruiting
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • TQB2450
  • +2 more
  • Beijing, Beijing, China
  • +3 more
Feb 12, 2023

Esophageal Squamous Cell Carcinoma, Esophageal Tumors, Esophageal Diseases Trial (Anlotinib HCl, TQB2450)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +10 more
  • Anlotinib hydrochloride
  • TQB2450
  • (no location specified)
Feb 19, 2022

Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)

Not yet recruiting
  • Stage II-IIIB(N2) Non-small Cell Lung Cancer
  • TQB2450
  • +4 more
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Oct 26, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (TQB2450, Intensity modulated radiotherapy)

Recruiting
  • Nasopharyngeal Carcinoma
  • TQB2450
  • Intensity modulated radiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Hospital
Jun 16, 2021

Gastric Cancer, Gastroesophageal-junction Cancer Trial (IBI315, Oxaliplatin, Capecitabine)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • (no location specified)
Nov 2, 2022

Stage III Non-small-cell Lung Cancer Trial in China (TQB2450, Anlotinib, TQB2450(blank))

Recruiting
  • Stage III Non-small-cell Lung Cancer
  • TQB2450
  • +3 more
  • Hefei, Anhui, China
  • +35 more
Mar 15, 2022

Small-cell Lung Cancer Trial in Shanghai (TQB2450)

Recruiting
  • Small-cell Lung Cancer
  • TQB2450
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jan 25, 2021

Gynecological Cancer Trial in China (TQB2450, Anlotinib)

Unknown status
  • Gynecological Cancer
  • Beijing, Beijing, China
  • +4 more
Jan 10, 2021

Recurrent or Metastatic Cervical Cancer Trial in Jinan (TQB2450)

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • TQB2450
  • Jinan, Shangdong, China
    Qilu Hospital of Shandong University
Nov 9, 2020

Safety and Effectiveness Trial in Beijing (TQB2450)

Unknown status
  • Safety and Effectiveness
  • TQB2450
  • Beijing, China
    No.17, panjiayuan nanli, chaoyang district, Beijing
Oct 8, 2020

Advanced Endometrial Cancer Trial in China (TQB2450, Anlotinib)

Recruiting
  • Advanced Endometrial Cancer
  • Hefei, Anhui, China
  • +35 more
Aug 17, 2021

Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL) Trial in China (TQB2450)

Terminated
  • Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
  • TQB2450
  • Beijing, Beijing, China
  • +17 more
Jan 21, 2021

Advanced Oligometastatic NSCLC Trial in Beijing, Shanghai, Tianjin (TQB2450, SBRT)

Not yet recruiting
  • Advanced Oligometastatic Non-small Cell Lung Cancer
  • TQB2450
  • SBRT
  • Beijing, Beijing, China
  • +3 more
Mar 12, 2020

Advanced Renal Cancer Trial in China (TQB2450, Anlotinib, Sunitinib)

Recruiting
  • Advanced Renal Cancer
  • TQB2450
  • +2 more
  • Hefei, Anhui, China
  • +25 more
Sep 9, 2020

Advanced Solid Tumors Trial in Chang chun (TQB2450, Anlotinib)

Unknown status
  • Advanced Solid Tumors
  • Chang chun, Jilin, China
    Jilin Cancer Hospital
Oct 29, 2019

Advanced Cholangiocarcinoma Trial in Beijing (Anlotinib, TQB2450)

Unknown status
  • Advanced Cholangiocarcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2019

Advanced Acral Malignant Melanoma Trial in Beijin (Anlotinib, TQB2450)

Unknown status
  • Advanced Acral Malignant Melanoma
  • Beijin, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2019

NSCLC Trial in Lanzhou, Luoyan, Changchun (TQB2450, Anlotinib)

Unknown status
  • Non-small Cell Lung Cancer
  • Lanzhou, Gansu, China
  • +2 more
Oct 29, 2019

Extensive Small Cell Lung Cancer Trial in China (TQB2450, Anlotinib, Etoposide)

Not yet recruiting
  • Extensive Small Cell Lung Cancer
  • TQB2450
  • +5 more
  • Bengbu, Anhui, China
  • +25 more
Jan 18, 2020

Lung Cancer Trial in Guangzhou (TQB2450, Anlotinib)

Unknown status
  • Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 13, 2019

Tumor Trial (TQB2450)

Unknown status
  • Tumor
  • TQB2450
  • (no location specified)
Mar 2, 2018